

Imaging Mass Cytometry Publications

October 31, 2021

This bibliography contains references to peer-reviewed publications featuring Imaging Mass Cytometry™ (IMC™) through October 31, 2021. Also included are non-peer-reviewed articles (for example, articles in *bioRxiv* and *Research Square*) and selected reviews of interest. The number of peer-reviewed publications is expected to reach nearly 140 by the end of the year.

2021 Publications

- 1 Alexander, M.P. et al. “Acute kidney injury in severe COVID-19 has similarities to sepsis-associated kidney injury: a multi-omics study.” *Mayo Clinic Proceedings* 96 (2021): 2,561–2,575.
- 2 Allam, M. et al. “Spatially visualized single-cell pathology of highly multiplexed protein profiles in health and disease.” *Communications Biology* 4 (2021): 632.
- 3 Avigan, Z.M. et al. “Tubular cell dropout in preimplantation deceased donor biopsies as a predictor of delayed graft function.” *Transplantation Direct* 7 (2021): e716
- 4 Baars, M.J.D. et al. “MATISSE: a method for improved single cell segmentation in Imaging Mass Cytometry™.” *BMC Biology* 19 (2021): 99.
- 5 Baranski, A. et al. “MAUI (MBI Analysis User Interface)—An image processing pipeline for multiplexed mass based imaging.” *PLoS Computational Biology* 17 (2021): e1008887.
- 6 Bertocchi, A. et al. “Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver.” *Cancer Cell* 39 (2021): 708–724.e11.
- 7 Bortolomeazzi, M. et al. “Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts.” *Gastroenterology* 161 (2021): 1,179–1,193.
- 8 Chen, C. et al. “Imaging Mass Cytometry™ reveals generalised deficiency in OXPPOS complexes in Parkinson’s disease.” *npj Parkinson’s Disease* 7 (2021): 39.

- 9 Elaldi, R. et al. “High dimensional Imaging Mass Cytometry™ panel to visualize the tumor immune microenvironment contexture.” *Frontiers in Immunology* 12 (2021): 666233.
- 10 Flint, L.E. et al. “Comparison of osteosarcoma aggregated tumour models with human tissue by multimodal mass spectrometry imaging.” *Metabolites* 11 (2021): 506.
- 11 Fonkoua, L.A.K. et al. “Outcomes on anti-VEGFR-2/paclitaxel treatment following progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma.” *International Journal of Cancer* 149 (2021): 378–386.
- 12 Garcia-Melchor, E. et al. “Novel self-amplificatory loop between T cells and tenocytes as driver of chronicity in tendon disease.” *Annals of Rheumatic Diseases* 80 (2021): 1,075–1,085.
- 13 Georgopoulou, D. et al. “Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response.” *Nature Communications* 12 (2021): 1998.
- 14 Gerdtsen, A.S. et al. “Large extracellular vesicle characterization and association with circulating tumor cells in metastatic castrate resistant prostate cancer.” *Cancers* 13 (2021): 1056.
- 15 Geuenich, M. et al. “Automated assignment of cell identity from single-cell multiplexed imaging and proteomic data.” *Cell Systems* 12 (2021): 1–14.
- 16 Guo, Q. et al. “The MNK1/2-eIF4E axis supports immune suppression and metastasis in postpartum breast cancer.” *Cancer Research* 81 (2021): 3,876–3,889.
- 17 Haeckel, A. et al. “Long-circulating XTEN864-annexin A5 fusion protein for phosphatidylserine-related therapeutic applications.” *Apoptosis* 26 (2021): 534–547.
- 18 Ijsselsteijn, M.E., Somarakis, A. et. al. “Semi-automated background removal limits data loss and normalizes Imaging Mass Cytometry™ data.” *Cytometry Part A* (2021): <https://doi.org/10.1002/cyto.a.24480>.
- 19 Jia, W. et al. “Case report: transformation from cold to hot tumor in a case of NSCLC neoadjuvant immunochemotherapy pseudoprogression.” *Frontiers in Immunology* 12 (2021): 633534.
- 20 Kondo, A. et al. “Highly Multiplexed Image Analysis of Intestinal Tissue Sections in Patients With Inflammatory Bowel Disease.” *Gastroenterology* 161 (2021): 1,940–1,952.

- 21** Lehmann, M. et al. “Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8⁺ T cells.” *Mucosal Immunology* 14 (2021): 1,381–1,392.
- 22** Li, R. et al. “Characterization of the tumor immune microenvironment in lung squamous cell carcinoma using Imaging Mass Cytometry™.” *Frontiers in Oncology* 11 (2021): 620989.
- 23** Lin, Y-W.E. et al. “Graph of graphs analysis for multiplexed data with application to Imaging Mass Cytometry™.” *PLOS Computational Biology* (2021): e1008741.
- 24** Liu, H-C. et al. “Potentiating antitumor efficacy through radiation and sustained intratumoral delivery of anti-CD40 and anti-PDL1.” *International Journal of Radiation Oncology Biology Physics* 110 (2021): 492–506.
- 25** Lutter, L. et al. “Homeostatic function and inflammatory activation of ileal CD8⁺ tissue-resident T cells is dependent on mucosal location.” *Cellular and Molecular Gastroenterology and Hepatology* 12 (2021): 1,567–1,581.
- 26** Martinez-Morilla, S. et al. “Biomarker discovery in immunotherapy-treated melanoma patients with Imaging Mass Cytometry™.” *Clinical Cancer Research* 27 (2021): 1,987–1,996.
- 27** McDowell, S.A.C. et al. “Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration.” *Nature Cancer* 2 (2021): 545–562.
- 28** Mitamura, Y. et al. “Cutaneous and systematic hyperinflammation drives maculopapular drug exanthema in severely ill COVID-19 patients.” *Allergy* (2021): doi:10.1111/all.14983.
- 29** Olaloye, O.O. et al. “CD16⁺CD163⁺ monocytes traffic to sites of inflammation during necrotizing enterocolitis in premature infants.” *Journal of Experimental Medicine* 218 (2021): e20200344.
- 30** Patel, J. et al. “Highly multiplexed mass cytometry identifies the immunophenotype in the skin of dermatomyositis.” *Journal of Investigative Dermatology* 141 (2021): 2,151–2,160.
- 31** Peran, I. et al. “Cadherin 11 promotes immunosuppression and extracellular matrix deposition to support growth of pancreatic tumors and resistance to gemcitabine in mice.” *Gastroenterology* 160 (2021): 1,359–1,372.
- 32** Rana, R. et al. “An iodinated DAPI-based reagent for mass cytometry.” *ChemBioChem* 3 (2021): 532–538.
- 33** Rendeiro, A.F. “The spatial landscape of lung pathology during COVID-19 progression”. *Nature* 593 (2021): 564–569.

- 34** Sanmamed, M.F. et al. “A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy.” *Cancer Discovery* 11 (2021): 1,700–1,715.
- 35** Schlect, A. et al. “Imaging Mass Cytometry™ for high-dimensional tissue profiling in the eye.” *BMC Ophthalmology* 21 (2021): 338.
- 36** Schwabenland, M. et al. “Deep spatial profiling of COVID-19 brains reveals neuroinflammation by compartmentalized local immune cell interactions and targets for intervention.” *Immunity* 7 (2021): 1594–1610.e11.
- 37** Sheng, J. et al. “Topological analysis of hepatocellular carcinoma tumour microenvironment based on Imaging Mass Cytometry™ reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.” *Gut* (2021): doi:10.1136/gutjnl-2021-324339.
- 38** Silva, R.V. et al. “Contribution of tissue inflammation and blood-brain barrier disruption to brain softening in a mouse model of multiple sclerosis.” *Frontiers in Neuroscience* 15 (2021): 701308.
- 39** Sinha, V.C. et al. “Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast.” *Nature Communications* 12 (2021): 5024.
- 40** Somarakis, A. et al. “ImaCytE: visual exploration of cellular micro-environments for Imaging Mass Cytometry™ data.” *IEEE Transactions on Visualization and Computer Graphics* 27 (2021): 98–110.
- 41** Somasundaram, R. et al. “Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.” *Nature Communications* 12 (2021): 346.
- 42** Spiteri, A.G. et al. “High-parameter cytometry unmasks microglial cell spatio-temporal response kinetics in severe neuroinflammatory disease.” *Journal of Neuroinflammation* 18 (2021): 166.
- 43** Strittmatter, N. et al. “Method to investigate the distribution of water-soluble drug-delivery systems in fresh frozen tissues using Imaging Mass Cytometry™.” *Analytical Chemistry* 93 (2021): 3,742–3,749.
- 44** Traum, D. et al. “Highly multiplexed 2-dimensional Imaging Mass Cytometry™ analysis of HBV-infected liver.” *JCI Insight* 6 (2021): 146883.
- 45** Van Maldegem, F. et al. “Characterisation of tumour immune microenvironment remodelling following oncogene inhibition in preclinical studies using an optimised Imaging Mass Cytometry™ workflow.” *Nature Communications* 12 (2021): 5906.
- 46** Wu, M. et al. “Single-cell analysis of human pancreas in type 2 diabetes using multi-spectral Imaging Mass Cytometry™.” *Cell Reports* 37 (2021): 109919.

- 47** Xiao, X. et al. “Dice-XMBD: deep learning-based cell segmentation for Imaging Mass Cytometry™.” *Frontiers in Genetics* 12 (2021): 721229.
- 48** Xie, S. et al. “Hyperion™ image analysis depicts a preliminary landscape of tumor immune microenvironment in OSCC with lymph node metastasis.” *Journal of Immunology Research* 2021 (2021): 9975423.
- 49** Yoo, K.H. et al. “Nicotinamide mononucleotide prevents cisplatin-induced cognitive impairments.” *Cancer Research* 81 (2021): 3,727–3,737.
- 50** Yuqin, Y. et al. “Tumor-infiltrating cytotoxic T cells and tumor-associated macrophages correlate with the outcomes of neoadjuvant chemoradiotherapy for locally advanced rectal cancer.” *Frontiers in Oncology* 11: 743540.
- 51** Zhu, Y. et al. “SIO: A spatioimageomics pipeline to identify prognostic biomarkers associated with the ovarian tumor microenvironment.” *Cancers* 13 (2021): 1777.

2021 Non-Peer-Reviewed Publications

- 1** Baker, D. et al. “A cellular reference resource for the mouse urinary bladder.” *bioRxiv* (2021): doi:10.1101/2021.09.20.461121.
- 2** Billi, A.C. et al. “Non-lesional and lesional lupus skin share inflammatory phenotypes that drive activation of CD16+ dendritic cells.” *bioRxiv* (2021): doi:10.1101/2021.09.17.460124.
- 3** Chen, H. et al. “Evaluation of cell segmentation methods without reference segmentations.” *bioRxiv* (2021): doi:10.1101/2021.09.17.460800.
- 4** Colombo, A. et al. “Single-cell spatial analysis of tumor immune architecture in diffuse large B cell lymphoma.” *medRxiv* (2021): doi:10.1101/2021.02.01.21250775v1.
- 5** Cross, A.R. et al. “Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune circuits related to tissue injury.” *bioRxiv* (2021): doi:10.1101/2021.06.21.449178.
- 6** Dolcetti, L. et al. “RUNIMC: An R-based package for imaging mass cytometry data analysis and pipeline validation.” *bioRxiv* (2021): doi:10.1101/2021.09.14.460258.
- 7** Hipps, D. et al. “Detecting respiratory chain deficiency in osteoblasts of older patients.” *medRxiv* (2021): doi:10.1101/2021.10.06.21264231.

- 8 Mugarza, E. et al. “Therapeutic KRAS^{G12C} inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers.” *bioRxiv* (2021): doi:10.1101/2021.10.18.464819.
- 9 Ravi, V.M. et al. “Spatiotemporal heterogeneity of glioblastoma is dictated by microenvironmental interference.” *bioRxiv* (2021): doi:10.1101/2021.02.16.431475v1.

2021 Selected Reviews and Commentary

- 1 Devine, R.D. and Behbehani, G.K. “Mass cytometry, Imaging Mass Cytometry™ and multiplexed ion beam imaging use in a clinical setting.” *Clinical Lab Medicine* 41 (2021): 297–308.
- 2 Irmisch, A. et al. “The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support.” *Cancer Cell* 39 (2021): 288–293.
- 3 Leroux, O., et al. “Imaging Mass Cytometry™: a promising multiplex detection tool for plant science research.” *Molecular Plant* 14 (2021): 1,241–1,243.
- 4 Lin, D. et al. “Imaging Mass Cytometry™.” *Imaging Modalities for Biological and Preclinical Research: a Compendium, Volume 1* (2021): I.9.h-1–I.9.h-9.
- 5 Naderi-Azad S. et al. “Research techniques made simple: experimental methodology for Imaging Mass Cytometry™.” *Journal of Investigative Dermatology* 141 (2021): 467–473.
- 6 Nederlof, I. et al. “A high-dimensional window into the microenvironment of triple negative breast cancer.” *Cancers* 13 (2021): 316.
- 7 Tracey, L.J. et al. “CyTOF®: an emerging technology for single-cell proteomics in the mouse.” *Current Protocols* 1 (2021): e118.
- 8 Veenstra, J. et al. “Research techniques made simple: use of Imaging Mass Cytometry™ for dermatological research and clinical applications.” *Journal of Investigative Dermatology* 141 (2021): 705–712.

2020 Publications

- 1 Aguilar-Navarro, A.G. et al. “Human aging alters the spatial organization between CD34+ hematopoietic cells and adipocytes in bone marrow.” *Stem Cell Reports* 15 (2020): 317–325.
- 2 Ali, H.R. et al. “Imaging Mass Cytometry™ and multiplatform genomics define the phenogenomic landscape of breast cancer.” *Nature Cancer* 1 (2020): 163–175.

- 3 Aoki, T. et al. “Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma.” *Cancer Discovery* 10 (2020): 406–421.
- 4 Batth, I.S. et al. “Rare osteosarcoma cell subpopulation protein array and profiling using Imaging Mass Cytometry™ and bioinformatics analysis.” *BMC Cancer* 20 (2020): 715.
- 5 Böttcher, C. et al. “Single-cell mass cytometry reveals complex myeloid cell composition in active lesions of progressive multiple sclerosis.” *Acta Neuropathologica Communications* 8 (2020): 136.
- 6 Chen, P.Y. et al. “Smooth muscle cell reprogramming in aortic aneurysms.” *Cell Stem Cell* 26 (2020): 542–557.
- 7 De Vries, N.L. et al. “Unraveling the complexity of the cancer microenvironment with multidimensional genomic and cytometric technologies.” *Frontiers in Oncology* 10 (2020): 1254.
- 8 Dey, P. et al. “Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer Cells utilizes cytokines from the tumor microenvironment.” *Cancer Discovery* 4 (2020): 608–625.
- 9 Eling, N. et al. “cytomapper: an R/Bioconductor package for visualization of highly multiplexed imaging data.” *Bioinformatics* 36 (2020): 5,706–5,708
- 10 Flint, L.E. et al. “Characterization of an aggregated three-dimensional cell culture model by multimodal mass spectrometry imaging.” *Analytical Chemistry* 92 (2020): 12,538–12,547.
- 11 Grenier, L. et al. “Enabling indium channels for mass cytometry by using reinforced cyclam-based chelating polylysine.” *Bioconjugate Chemistry* 31 (2020) 2,013–2,115.
- 12 Gudjonsson, J.E. et al. “Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis.” *JCI Insight* 5 (2020): e139930.
- 13 Guo, N. et al. “A 34-marker panel for imaging mass cytometric analysis of human snap-frozen tissue.” *Frontiers in Immunology* 11 (2020): 1466.
- 14 Jackson, H.W. et al. “The single-cell pathology landscape of breast cancer.” *Nature* 578 (2020): 615–620.
- 15 Loeuillard, E. et al. “Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.” *The Journal of Clinical Investigation* 130 (2020): 5,380–5,396.
- 16 Podojil, J.R. et al. “Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma.” *Oncoimmunology* 9 (2020): e1744897.

- 17 Savic, L.J. et al. “Molecular MRI of the immuno-metabolic interplay in a rabbit liver tumor model: a biomarker for resistance mechanisms in tumor-targeted therapy?” *Radiology* 296 (2020): 575–583.
- 18 Umemoto, K. et al. “The potential application of PD-1 blockade therapy for early-stage biliary tract cancer.” *International Immunology* 32 (2020): 273–281.
- 19 Vurgun, N. and Nitz, M. “Validation of l-tellurienylalanine as a phenylalanine isostere.” *ChemBioChem* 21 (2020): 1,136–1,139.
- 20 Wang C. et al. “Imaging mass cytometric analysis of postmortem tissues reveals dysregulated immune cell and cytokine responses in multiple organs of COVID-19 patients.” *Frontiers in Microbiology* 11 (2020): 600989.
- 21 Warren, C. et al. “Decoding mitochondrial heterogeneity in single muscle fibres by Imaging Mass Cytometry™.” *Scientific Reports* 10 (2020): 15336.
- 22 Xiang, H. et al. “Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma.” *Cancer Immunology Research* 8 (2020): 436–450.
- 23 Xie, S. et al. “Hyperion™ Imaging System reveals tumor microenvironment of oral squamous cell carcinoma patients at T1N0M0 stage.” *Annals of Translational Medicine* 22 (2020): 1513.
- 24 Yu, Y. et al. “Metal-labeled aptamers as novel nanoprobe for Imaging Mass Cytometry™.” *Analytical Chemistry* 92,9 (2020): 6,312–6,320.
- 25 Zanotelli, V.R. et al. “A quantitative analysis of the interplay of environment, neighborhood, and cell state in 3D spheroids.” *Molecular Systems Biology* 16 (2020): e9798.
- 26 Zhang, Y. et al. “Inflammatory response cells during acute respiratory distress syndrome in patients with coronavirus disease 2019 (COVID-19).” *Annals of Internal Medicine* 173 (212/14/2021020): 402–404.
- 27 Zhang, Y. et al. “A systematic comparison of *in vitro* cell uptake and *in vivo* biodistribution for three classes of gold nanoparticles with saturated PEG coatings.” *PLoS ONE* 15 (2020): e0234916.

2020 Non-Peer-Reviewed Publications

- 1 Catena, R. et al. “Highly multiplexed molecular and cellular mapping of breast cancer tissue in three dimensions using mass tomography.” *bioRxiv* (2020): doi.org/10.1101/2020.05.24.113571.

2020 Selected Reviews and Commentary

- 1 Fernandez-Zapata C. et al. “The use and limitations of single-cell mass cytometry for studying human microglia function.” *Brain Pathology* (2020): 1,178–1,191.

2019 Publications

- 1 Arnol, D. et al. “Modeling cell-cell interactions from spatial molecular data with spatial variance component analysis.” *Cell Reports* 29 (2019): 202–211.e6.
- 2 Bassan, J. et al. “Methods for analyzing tellurium imaging mass cytometry data.” *PLoS ONE* 14 (2019): e0221714.
- 3 Bassan, J. et al. “TePhe, a tellurium-containing phenylalanine mimic, allows monitoring of protein synthesis *in vivo* with mass cytometry.” *Proceedings of the National Academy of Sciences of the United States of America* 116 (2019): 8,155–8,160.
- 4 Bouzekri, A. et al. “Multidimensional profiling of drug-treated cells by Imaging Mass Cytometry™.” *FEBS Open Bio* (2019): 1,652–1,669.
- 5 Cao, Y. et al. “Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy.” *Cancer Chemotherapy and Pharmacology* 84 (2019) 1,195–1,200.
- 6 Carvajal-Hausdorf, D.E. et al. “Multiplexed (18-plex) measurement of signaling targets and cytotoxic T cells in trastuzumab-treated patients using Imaging Mass Cytometry™.” *Clinical Cancer Research* 25 (2019): 3,054–3,062.
- 7 Cheng, R. et al. “Periodontal inflammation recruits distant metastatic breast cancer cells by increasing myeloid-derived suppressor cells.” *Oncogene* 39 (2019): 1,543–1,556.
- 8 Damond, N. et al. “A map of human type 1 diabetes progression by Imaging Mass Cytometry™.” *Cell Metabolism* 29 (2019): 755–768.
- 9 Datar, I. et al. “Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis.” *Clinical Cancer Research* (2019): 4,663–4,673.
- 10 Durand, M. et al. “Human lymphoid organ cDC2 and macrophages play complementary roles in T follicular helper responses.” *Journal of Experimental Medicine* 216 (2019): 1,561–1,581.

- 11** Elyada, E. et al. “Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting antigen-associated fibroblasts.” *Cancer Discovery* (2019): 1,102–1,123.
- 12** Guo, R. et al. “Lymphocyte mass cytometry identifies a CD3–CD4⁺ cell subset with a potential role in psoriasis.” *JCI Insight* 4 (2019): 125306.
- 13** Ijsselsteijn, M.E et al. “A 40-marker panel for high dimensional characterization of cancer immune microenvironments by Imaging Mass Cytometry™.” *Frontiers in Immunology* 10 (2019): 2534.
- 14** Li, N. et al. “Early-life compartmentalization of immune cells in human fetal tissues revealed by high-dimensional mass cytometry.” *Frontiers in Immunology* 10 (2019): 1932.
- 15** Li, N. et al. “Memory CD4⁺ T cells are generated in the human fetal intestine.” *Nature Immunology* 20 (2019): 301–312.
- 16** Malile, B. et al. “DNA-conjugated gold nanoparticles as high-mass probes in Imaging Mass Cytometry™.” *ACS Applied Bio Materials* 2 (2019): 4,316–4,323.
- 17** Park, C. et al. “The landscape of myeloid and astrocyte phenotypes in acute multiple sclerosis lesions.” *Acta Neuropathologica Communications* 7 (2019): 130.
- 18** Popescu, D-M. et al. “Decoding the development of the blood and immune systems during human fetal liver haematopoiesis.” *Nature* 574 (2019): 365–371.
- 19** Raj, D. et al. “Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.” *Gut* 68 (2019): 1,052–1,064.
- 20** Ramaglia, V. et al. “Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry.” *eLife* 8 (2019): e48051.
- 21** Rana, R. et al. “Signal amplification for Imaging Mass Cytometry™.” *Bioconjugate Chemistry* 30 (2019): 2,805–2,810.
- 22** Singh, N. et al. “Development of a 2-dimensional atlas of the human kidney with Imaging Mass Cytometry™.” *JCI Insight* 4 (2019): 129477.
- 23** Somarakis, A. et al. “ImaCytE: visual exploration of cellular microenvironments for Imaging Mass Cytometry™ data.” *IEEE Transactions on Visualization and Computer Graphics* (2019): 98–110.
- 24** Theil, D. et al. “Imaging Mass Cytometry™ and single-cell genomics reveal differential depletion and repletion of B-cell populations following ofatumumab treatment in cynomolgus monkeys.” *Frontiers in Immunology* 10 (2019): 1340.

- 25** Umemoto, K. et al. “The potential application of PD-1 blockade therapy for early-stage biliary tract cancer.” *International Immunology* 32 (2019): 273–281.
- 26** Uraki, R. et al. “*Aedes aegypti* AgBR1 antibodies modulate early Zika virus infection of mice.” *Nature Microbiology* 4 (2019): 948–955.
- 27** Wang, Y.J. et al. “Multiplexed *in situ* Imaging Mass Cytometry™ analysis of the human endocrine pancreas and immune system in type 1 diabetes.” *Cell Metabolism* 29 (2019): 769–783.
- 28** Zhang, T. et al. “Immunocyte profiling using single-cell mass cytometry reveals EpCAM+ CD4+ T cells abnormal in colon cancer.” *Frontiers in Immunology* 10 (2019): 1571.

2018 Publications

- 1** Allo, B. et al. “Clickable and high sensitivity metal-containing tags for mass cytometry.” *Bioconjugate Chemistry* 29 (2018): 2,028–2,038.
- 2** Brahler, S. et al. “Opposing roles of dendritic cell subsets in experimental GN.” *Journal of the American Society of Nephrology* 29 (2018): 138–154.
- 3** Brodie, T.M. and Tosevski, V. “Broad immune monitoring and profiling of T cell subsets with mass cytometry.” *Methods in Molecular Biology* 1745 *Cellular Heterogeneity* (2018): 67–82.
- 4** Catena, R. et al. “Ruthenium counterstaining for Imaging Mass Cytometry™.” *The Journal of Pathology* 244 (2018): 479–484.
- 5** Cao, Y. et al. “Tumor platinum concentrations and pathological responses following cisplatin-containing chemotherapy in gastric cancer patients.” *Journal of Gastrointestinal Cancer* (2018): 801–807.
- 6** Chevrier, S. et al. “Compensation of signal spillover in suspension and Imaging Mass Cytometry™.” *Cell Systems* 6 (2018): 612–620.
- 7** Gerdtsson, E. et al. “Multiplex protein detection on circulating tumor cells from liquid biopsies using Imaging Mass Cytometry™.” *Convergent Science Physical Oncology* 4 (2018): 015002.
- 8** Malihi, P.D. et al. “Clonal diversity revealed by morphoproteomic and copy number profiles of single prostate cancer cells at diagnosis.” *Convergent Science Physical Oncology* 4 (2018): 015003.
- 9** Schulz, D. et al. “Simultaneous multiplexed imaging of mRNA and proteins with subcellular resolution in breast cancer tissue samples by mass cytometry.” *Cell Systems* 6 (2018): 25–36.

- 10 Zhao, Y. et al. "Spatiotemporal segregation of human marginal zone and memory B cell populations in lymphoid tissue." *Nature Communications* 9 (2018): 3857.

2018 Non-Peer-Reviewed Publications

- 1 Strobl, M. et al. "Connecting the microenvironmental niche to treatment response in ovarian cancer." *bioRxiv* (2018): doi.org/10.1101/452052.

2017 Publications

- 1 Chang, Q. et al. "Imaging Mass Cytometry™." *Cytometry Part A* 91 (2017): 160–169.
- 2 Chang, Q. et al. "Staining of frozen and formalin-fixed, paraffin-embedded tissues with metal-labeled antibodies for Imaging Mass Cytometry™ analysis." *Current Protocols in Cytometry* 82 (2017): 12.47.1–12.47.8.
- 3 Mavropoulos, A. et al. "Simultaneous detection of protein and mRNA in Jurkat and KG-1a cells by mass cytometry." *Cytometry Part A* 91 (2017): 1,200–1,208.
- 4 Schapiro, D. et al. "histoCAT™: analysis of cell phenotypes and interactions in multiplex image cytometry data." *Nature Methods* 14 (2017): 873–876.
- 5 Singh, M. et al. "Highly multiplexed Imaging Mass Cytometry™ allows visualization of tumor and immune cell interactions of the tumor microenvironment in FFPE tissue sections." *Blood* 130 (2017): 2,751.
- 6 Straus, R.N. et al. "Analytical figures of merit for a novel tissue imaging system." *Journal of Analytical Atomic Spectrometry* 32 (2017): 1,044–1,051.

2017 Non-Peer-Reviewed Publications

- 1 Sivakamasundari, V. et al. "Comprehensive cell type specific transcriptomics of the human kidney." *bioRxiv* (2017): doi.org/10.1101/238063.

2016 Publications

- 1 Chang, Q. et al. “Biodistribution of cisplatin revealed by Imaging Mass Cytometry™ identifies extensive collagen binding in tumor and normal tissues.” *Scientific Reports* 6 (2016): 36,641.
- 2 Edgar, L.J. et al. “Isotopologous organotellurium probes reveal dynamic hypoxia *in vivo* with cellular resolution.” *Angewandte Chemie International Edition* 55 (2016): 13,159–13,163.

2015 Publications

- 1 Schüffler, P.J. et al. “Automatic single cell segmentation on highly multiplexed tissue images.” *Cytometry Part A* 87 (2015): 936–942.

2014 Publications

- 1 Giesen, C. et al. “Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry.” *Nature Methods* 11 (2014): 417–422.

CORPORATE HEADQUARTERS

2 Tower Place, Suite 2000
South San Francisco, CA 94080 USA
Toll-free: 866 359 4354 in the US and Canada
Fax: 650 871 7152
fluidigm.com

SALES

North America | +1 650 266 6170 | info-us@fluidigm.com
Europe/EMEA | +33 1 60 92 42 40 | info-europe@fluidigm.com
China (excluding Hong Kong) | +86 21 3255 8368 | info-china@fluidigm.com
Japan | +81 3 3662 2150 | info-japan@fluidigm.com
All other Asian countries | +1 650 266 6170 | info-asia@fluidigm.com
Latin America | +1 650 266 6170 | info-latinamerica@fluidigm.com

For Research Use Only. Not for use in diagnostic procedures.

Information in this publication is subject to change without notice. Patent and license information: fluidigm.com/legal/notices. Limited Use Label License: The purchase of this Fluidigm Instrument and/or Consumable conveys to the purchaser the limited, nontransferable right to use with only with Fluidigm Consumables and/or Instruments respectively except as approved in writing by Fluidigm: www.fluidigm.com/legal/salesterms. Patents: www.fluidigm.com/legal/notices. Trademarks: Fluidigm, the Fluidigm logo, CyTOF, Hyperion, Imaging Mass Cytometry and IMC are trademarks and/or registered trademarks of Fluidigm Corporation or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. ©2021 Fluidigm Corporation. All rights reserved. 12/2021